Market Cap (In USD)
1007.00
Revenue (In USD)
-
Net Income (In USD)
-36.48 Million
Avg. Volume
372.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-5-0.0226
- PE
- -
- EPS
- -
- Beta Value
- 29.647
- ISIN
- CA44974L3011
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Andrew Hall M.Sc.
- Employee Count
- -
- Website
- https://www.imv-inc.com
- Ipo Date
- 2013-04-08
- Details
- IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
More Stocks
-
8462
-
OMU
-
NDA-SENordea Bank Abp
NDA-SE
-
4561
-
5947Rinnai Corporation
5947
-
WEHA
-
JITFINFRAJITF Infralogistics Limited
JITFINFRA
-
JEDT